Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S. Kittai, Philip A. Thompson, Caitlyn Duffy et al.|Journal of Clinical Oncology|2024Cited by 43
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S. Kittai, Jennifer A. Woyach, Ying Huang et al.|Blood Cancer Journal|2025Cited by 12
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Jennifer Santos, Jason T. Romancik, Loretta J. Nastoupil et al.|UNC Libraries|2024Cited by 0